Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06773624

Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel

Evaluation of 68Ga-DOTATOC PET/CT-enterography for the Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
18 (estimated)
Sponsor
European Institute of Oncology · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The neuroendocrine neoplasms of the small intestine (Si-NENs) is a relatively rare malignancy. Surgical resection is the only curative treatment for the early-stage. It remains controversial its application for advanced metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The identification of metastatic disease and tumor grade are the most important prognostic factors in advanced GEPNETs. Therefore, precise staging and evaluation of disease burden with a reliable imaging method is crucial for determining the correct stage of the disease and consequently the correct treatment. A unique feature of NeuroEndocrinal Tumors (NETs) is the expression of somatostatin receptors (SSTR) which can be targeted with radiolabeled peptides for imaging. The Positron Emission Tomography-Computed Tomography (PET/CT) technique using somatostatin analogs labeled with the positron emitting isotope, 68Ga (68Ga-DOTA peptides), has been shown to offer advantages over conventional imaging modalities as well as additional important quantitative and qualitative diagnostic information. The aim of this study is to calculate the sensitivity (SE), the specificity (SP), the positive and negative predictive values (PPV and NPV) and the overall accuracy of 68Ga-DOTATOC PET/CT-enterography in detecting in primary lesion and multifocality of siNETs.

Conditions

Interventions

TypeNameDescription
OTHERPET/CT-enterography with 68Ga-DOTATOCPatients underwent to PET/CT-enterography with 68Ga-DOTATOC

Timeline

Start date
2021-04-23
Primary completion
2026-12-01
Completion
2026-12-01
First posted
2025-01-14
Last updated
2025-01-14

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06773624. Inclusion in this directory is not an endorsement.